Immunic Therapeutics
Immunic is a biotechnology company developing small molecule therapies for chronic inflammatory and autoimmune diseases
Immunic is a biotechnology company developing small molecule therapies for chronic inflammatory and autoimmune diseases
Immunic Therapeutics is a biotechnology company founded in 2016 and headquartered in the United States. The company's focus lies in the development of small molecule therapies for chronic inflammatory and autoimmune diseases. Immunic, listed on Nasdaq under the ticker symbol IMUX, boasts a clinical pipeline of orally administered treatments designed to address these conditions. The latest significant milestone for Immunic was a $240.00MPost-IPO Equity investment, which took place on 04 January 2024. This round of investment saw participation from major players in the investment landscape, including Adage Capital Management, BVF Partners, Janus Handerson, RTW Investments, Soleus Capital, and Avidity Partners. Through this, Immunic has solidified its standing and financial backing, positioning itself for further growth and industry impact in the realm of biotechnology.
Immunic's slogan is: "Immunic is a biotechnology company developing small molecule therapies for chronic inflammatory and autoimmune diseases". The company's Privacy Policy can be found at: https://imux.com/privacy-policy/
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $240.00M | 6 |
|
04 Jan 2024 |
| Post-IPO Equity | $60.00M | 10 |
|
10 Oct 2022 |
| Post-IPO Equity | $45.00M | - | 15 Jul 2021 | |
| Post-IPO Equity | $103.50M | - | 04 Aug 2020 | |
| Post-IPO Equity | $25.00M | - | 09 Jun 2020 |
No recent news or press coverage available for Immunic Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
